Table 5.
Relationships Between F1+2 and Clinical Outcomes Based on OAC Use
| F1+2 (pmol/L) | Warfarin (n = 728) |
DOAC (n = 2,289) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Incidence Rate, /100 py | HR (95% CI) | P Value | n | Incidence Rate, /100 py | HR (95% CI) | P Value | ||
| Stroke/SEE | <69 | 165 | 2.22 | 1.96 (0.71-5.44) | 0.195 | 8 | 6.83 | 6.66 (0.84-53.09) | 0.073 |
| 69 to <229 | 480 | 1.60 | Reference | - | 1,585 | 1.34 | Reference | - | |
| ≥229 | 83 | 4.92 | 2.58 (0.87-7.70) | 0.089 | 696 | 1.95 | 1.54 (0.91-2.59) | 0.105 | |
| Major bleeding | <69 | 165 | 0.00 | 0.00 (-, -) | - | 8 | 0.00 | 0.00 (-, -) | - |
| 69 to <229 | 480 | 0.91 | Reference | - | 1,585 | 0.97 | Reference | - | |
| ≥229 | 83 | 2.74 | 3.53 (0.64-19.44) | 0.148 | 696 | 1.48 | 1.47 (0.80-2.71) | 0.212 | |
| ICH | <69 | 165 | 0.00 | 0.00 (-, -) | - | 8 | 0.00 | 0.00 (-, -) | - |
| 69 to <229 | 480 | 0.34 | Reference | - | 1,585 | 0.67 | Reference | - | |
| ≥229 | 83 | 1.36 | (-, -) | - | 696 | 1.16 | 1.84 (0.90-3.76) | 0.095 | |
| CV events | <69 | 165 | 5.96 | 0.87 (0.51-1.49) | 0.611 | 8 | 6.83 | 1.27 (0.17-9.66) | 0.818 |
| 69 to <229 | 480 | 9.93 | Reference | - | 1,585 | 5.28 | Reference | - | |
| ≥229 | 83 | 18.06 | 1.23 (0.74-2.07) | 0.425 | 696 | 7.55 | 1.31 (1.00-1.71) | 0.0496 | |
| CV death | <69 | 165 | 0.00 | 0.00 (-, -) | - | 8 | 0.00 | 0.00 (-, -) | - |
| 69 to <229 | 480 | 1.92 | Reference | - | 1,585 | 0.70 | Reference | - | |
| ≥229 | 83 | 4.02 | 0.92 (0.27-3.13) | 0.888 | 696 | 1.54 | 1.79 (0.93-3.45) | 0.080 | |
| All-cause death | <69 | 165 | 0.94 | 0.21 (0.06-0.70) | 0.011 | 8 | 0.00 | 0.00 (-, -) | - |
| 69 to <229 | 480 | 5.66 | Reference | - | 1,585 | 2.39 | Reference | - | |
| ≥229 | 83 | 10.04 | 1.18 (0.61-2.29) | 0.614 | 696 | 4.15 | 1.47 (1.01-2.13) | 0.044 | |